Daniel J. Hicklin

52.9k citations
185 papers · 35.4k indexed · 15 hit papers · h-index 91

Impact in

  • Cancer Research top 0.05%
    • Cancer, Hypoxia, and Metabolism
  • Oncology top 0.05%
    • Lymphatic System and Diseases
    • Cancer Cells and Metastasis
    • Colorectal Cancer Treatments and Studies
    • Cancer Treatment and Pharmacology

Papers in

    • Vascular Tumors and Angiosarcomas 20
    • HER2/EGFR in Cancer Research 16
    • Lymphatic System and Diseases 15
    • Cancer, Hypoxia, and Metabolism 44

Daniel J. Hicklin

183 papers receiving 34.4k citations

Hit Papers

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose 2008 · 1.1k citations
1.1k199920262008201750010001.5k2.0k

Peers

Daniel J. Hicklin
Comparison fields: 5 of 162
  • Cancer Research 8.8k
  • Oncology 14.0k
  • Molecular Biology 20.8k
  • Genetics 3.2k
  • Immunology and Allergy 1.6k
Replace Robert S. Kerbel with:
Robert S. Kerbel Canada
Shahin Rafii United States
Harold L. Moses United States
Isaiah J. Fidler United States
Carlos Cordon‐Cardo United States
Kevin C. Gatter United Kingdom
Amato J. Giaccia United States
Frances R. Balkwill United Kingdom
Ralph R. Weichselbaum United States
Max S. Wicha United States
Daniel J. Hicklin relative to Robert S. Kerbel Canada Robert S. Kerbel's profile →
Citations per field
00.5×1.5×
Robert S. Kerbel · 1×
Citations per year

Countries citing papers authored by Daniel J. Hicklin

Since Specialization
Citations

This map shows the geographic impact of Daniel J. Hicklin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Hicklin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Hicklin more than expected).

Fields of papers citing papers by Daniel J. Hicklin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Hicklin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Hicklin. The network helps show where Daniel J. Hicklin may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel J. Hicklin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel J. Hicklin Line = papers co-authored together Daniel J. Hicklin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20231
2 20238
3 201017
4
Tumor bed irradiation enhances sensitivity of A431 tumor xenografts to C225 anti-EGFR antibody
20081
5 2007184
6
IMC-A12 enhances the efficacy of cetuximab + gemcitabine therapy in human pancreatic carcinoma xenografts.
20073
7 2006105
8 2006126
9
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Hit paper breakdown →
20062037
10 2006127
11 2005470
12
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Hit paper breakdown →
2004976
13
Expression and function of vascular endothelial growth factor receptor–1 in human colon cancer cells
20041
14
Antitumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human tumor xenograft models
200413
15 200359
16
Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
200286
17 20008
18 2000139
19
Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis.
200099
20 199812

About Daniel J. Hicklin

Daniel J. Hicklin is a scholar working on Oncology, Cancer Research, Immunology and Allergy, Molecular Biology and Genetics, having authored 185 papers that have together received 35.4k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (102 papers), Cancer, Hypoxia, and Metabolism (44 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Vascular Tumors and Angiosarcomas (20 papers), HER2/EGFR in Cancer Research (16 papers), Lymphatic System and Diseases (15 papers), Immunotherapy and Immune Responses (14 papers) and Cell Adhesion Molecules Research (12 papers). The work is most often cited by research in Cancer Research (8.8k citations), Oncology (14.0k citations), Molecular Biology (20.8k citations), Genetics (3.2k citations) and Immunology and Allergy (1.6k citations). Daniel J. Hicklin has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Lee M. Ellis, Larry Witte, Peter Böhlen, Zhenping Zhu, Robert S. Kerbel, Shahin Rafii, Malcolm A.S. Moore, Shan Man, Francesco M. Marincola and Gabriele Bergers. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Blood, Journal of Clinical Investigation and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026